Buy, hold, sell: Pro Medicus, Fortescue, CBA shares

S&P/ASX 200 Index (ASX: XJO) shares are up 0.27% to 9,086.2 points as earnings season continues on Monday.

Among the 11 market sectors, materials and miners are in the lead today, up 1.7%.

The sector pushed higher amid BHP Group Ltd (ASX: BHP) shares reaching a new record of $67.72, up 3.9%, in early trading.

The financials sector is the laggard today, down 1%.

Let’s check out some new expert ratings on three ASX 200 sector heavyweights.

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price is $191.56, down 0.02% today and down 37% over 12 months. 

Pro Medicus shares jumped 7.1% last week after the company released its FY26 results.

The Pro Medicus share price is up 20% since the downtrodden healthcare sector pivoted on 3 June. 

Morgans maintained its accumulate rating on Pro Medicus shares after the report.

Analyst Iain Wilkie said: 

FY26 confirms PME is executing at an even higher level than the market gave it credit for. EBIT margin of 74.9% and constant currency EBIT growth of 30.6% both beat expectations comfortably, with the FX-driven softness in headline revenue a currency story, not a demand or execution one.

Momentum remains broad-based, implementations are ahead of schedule, renewals are a clean sweep, and the pipeline is opening up in new segments rather than just deepening in existing ones.

Looking ahead, FY27 is shaping as a genuine standout year. With four Trinity cohorts and 15 other implementations already banked rather than still ramping, the P&L gets the full run-rate benefit without needing fresh signings just to stand still.

Nothing in the result gives us any pause for change versus our positive view.

Fortescue Ltd (ASX: FMG)

The Fortescue share price is $18.08, up 1.8% today and down 10% over 12 months. 

Morgans has a hold rating on this ASX 200 mining share following the company’s FY26 report last week.

Analyst Adrian Prendergast said: 

A mixed FY26 result from FMG, with higher revenue helping to offset cost increases and elevated admin/R&D to help keep underlying earnings flat.

With the focus on FY27 guidance, Iron Bridge remained a key issue, with the magnetite operation struggling through ramp up and with elevated costs.

Plans for a green steel plant was big news, although difficult to quantify.

Commonwealth Bank of Australia (ASX: CBA)

The CBA share price is $155.24, down 1.7% today and down 9% over 12 months. 

CBA reported a 7% increase in its cash net profit after tax (NPAT) to $11 billion for FY26.

John Athanasiou from Red Leaf Securities has a sell rating on this ASX 200 bank share. 

He explained (courtesy The Bull):

CBA shares deserves to trade at a premium given its dominant retail franchise, strong technology platform, solid deposit base and consistent execution.

However, Australian banking remains a mature industry, with intense competition across mortgages and deposits limiting the potential for outsized earnings growth.

At a premium valuation, investors are paying a higher price for quality, leaving little room for disappointment.

After a substantial re-rating, investors may be better served taking some profits and reallocating capital towards businesses offering stronger growth at more reasonable valuations.